Torvutatug Samrotecan

萨康拓沃妥塔单抗

Report date: 2026/04/03 20:03:44

Base Information

Drug NameTorvutatug Samrotecan
Drug Alias NameAZD5335AZD-5335
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionAnti-FOLR1DNA topoisomerase I inhibitors
TargetsFolate receptor alphaDNA topoisomerase I
Therapy Area/IndicationsSolid tumoursPeritoneal DiseasesEndometrial Neoplasms +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[24] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesAstrazeneca Plc
China Registration ClassN/A

Develop Information

Active CompaniesAstrazeneca PlcAstrazeneca AbAstraZeneca global R & D (China) Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursPeritoneal DiseasesEndometrial Neoplasms +[7] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A